tesetaxel: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6918574 |
| CHEMBL ID | 2107787 |
| SCHEMBL ID | 12060837 |
| MeSH ID | M0506765 |
| Synonym |
|---|
| dj-927 |
| tesetaxel |
| unii-ug97lo5m8y |
| ug97lo5m8y , |
| dj 927 |
| tesetaxel [inn] |
| dj927 |
| 333754-36-2 |
| CHEMBL2107787 |
| tesetaxel [who-dd] |
| SCHEMBL12060837 |
| DB12019 |
| [(2r,4s,6s,7r,10r,13s,14r,15s,16s,18s)-13-acetyloxy-4-[(dimethylamino)methyl]-18-[(2r,3s)-3-(3-fluoropyridin-2-yl)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]oxy-16-hydroxy-7,19,20,20-tetramethyl-3,5,11-trioxapentacyclo[14.3.1.02,6.07,14 |
| Q7705452 |
| dj 927; |
| DTXSID00870326 |
| CS-0006362 |
| HY-16491 |
This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class. The drug is administered with oral capecitabine to patients with advanced solid tumors.
| Excerpt | Reference | Relevance |
|---|---|---|
| "This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors." | ( Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Beeram, M; Patnaik, A; Saif, MW; Sarantopoulos, J; Takimoto, C; Tolcher, AW, 2011) | 2.03 |
| " These data further support the continued clinical development of tesetaxel both as a single agent and in combination with other active cancer therapeutics." | ( Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Beeram, M; Patnaik, A; Saif, MW; Sarantopoulos, J; Takimoto, C; Tolcher, AW, 2011) | 2.05 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||